Free Trial
NASDAQ:ANIP

ANI Pharmaceuticals Q2 2025 Earnings Report

ANI Pharmaceuticals logo
$80.61 -0.50 (-0.62%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ANI Pharmaceuticals EPS Results

Actual EPS
$1.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ANI Pharmaceuticals Revenue Results

Actual Revenue
$211.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ANI Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

ANI Pharmaceuticals' Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

ANI Pharmaceuticals Earnings Headlines

The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.tc pixel
ANI Pharmaceuticals (ANIP) Gets a Buy from Barclays
See More ANI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email.

About ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ:ANIP) is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners.

Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.

View ANI Pharmaceuticals Profile